Resources from the same session
Association of survival and blood-based genomic signature with atezolizumab for patients with second-line and third-line EGFR wild-type non-small cell lung cancer: Pooled analysis of individual patient data from the POPLAR and OAK trials
Presenter: Yunfang Yu
Session: Mini Oral session - Immunotherapy of cancer
Resources:
Slides
Webcast
318O - Both low and high blood tumour mutational burden are favourable predictors with atezolizumab
Presenter: Wei Nie
Session: Mini Oral session - Immunotherapy of cancer
Resources:
Abstract
PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in NSCLC
Presenter: Jiaqing Liu
Session: Mini Oral session - Immunotherapy of cancer
Resources:
Slides
Webcast
Data-driven miRNA classifier as response predictor for immune checkpoint inhibitor treatment in advanced-stage cancer patients
Presenter: Chia-Hsun Hsieh
Session: Mini Oral session - Immunotherapy of cancer
Resources:
Slides
Webcast
LBA14 - Genomic HLA heterozygosity as a predictive marker for survival in lung cancer patients post immunotherapy
Presenter: Afaf Abed
Session: Mini Oral session - Immunotherapy of cancer
Resources:
Abstract
Slides
Webcast